Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia

Rituximab is an effective treatment for autoimmune cytopenias associated with chronic lymphocytic leukemia. Despite the incorporation of rituximab into fludarabine-based chemotherapy regimens, the incidence of autoimmune cytopenias has remained high. Inadequate rituximab exposure due to rapid antibo...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Mo, Clifton C., Njuguna, Ndegwa, Beum, Paul V., Lindorfer, Margaret A., Vire, Berengere, Lee, Elinor, Marti, Gerald, Wilson, Wyndham H, Taylor, Ronald P., Wiestner, Adrian
Format: Artigo
Jezik:Inglês
Izdano: Ferrata Storti Foundation 2013
Teme:
Original Articles and Brief Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3729907/
https://ncbi.nlm.nih.gov/pubmed/23716541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.080929
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items